{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:55:24Z","timestamp":1791320124165,"version":"4.3.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01388-5","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T15:33:45Z","timestamp":1761320025000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["From response to cure: Unaddressed clinical challenges in the Tali-cel\u2122 CD19 CAR-T trial for relapsed\/refractory pediatric B-cell acute lymphoblastic leukemia"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3404-8446","authenticated-orcid":false,"given":"Zhao","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangmin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0541-0696","authenticated-orcid":false,"given":"Shuang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"key":"1388_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01279-9","volume":"15","author":"G Narula","year":"2025","unstructured":"Narula G, Keerthivasagam S. Novel humanized CD19-CAR-T (Now talicabtagene autoleucel, Tali-cel\u2122) cells in relapsed\/ refractory pediatric B-acute lymphoblastic leukemia- an open-label single-arm phase-I\/Ib study. Blood Cancer J. 2025;15:75.","journal-title":"Blood Cancer J"},{"key":"1388_CR2","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1200\/JCO.22.00642","volume":"41","author":"TW Laetsch","year":"2023","unstructured":"Laetsch TW, Maude SL. Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA Trial. J Clin Oncol. 2023;41:1664\u20139.","journal-title":"J Clin Oncol"},{"key":"1388_CR3","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41417-023-00593-3","volume":"30","author":"M Elsallab","year":"2023","unstructured":"Elsallab M, Ellithi M. Long-term response to autologous anti-CD19 chimeric antigen receptor T cells in relapsed or refractory B cell acute lymphoblastic leukemia: a systematic review and meta-analysis. Cancer Gene Ther. 2023;30:845\u201354.","journal-title":"Cancer Gene Ther"},{"key":"1388_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1280580","volume":"14","author":"\u00c1 Molinos-Quintana","year":"2023","unstructured":"Molinos-Quintana \u00c1, Alonso-Saladrigues A, Herrero B, Caballero-Vel\u00e1zquez T, Gal\u00e1n-G\u00f3mez V, Panesso M, et al. Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse\/refractory acute lymphoblastic leukemia: role of B-cell monitoring. Front Immunol. 2023;14:1280580.","journal-title":"Front Immunol"},{"key":"1388_CR5","first-page":"674","volume":"29","author":"AJ Lamble","year":"2023","unstructured":"Lamble AJ, Moskop A, Pulsipher MA, Maude SL, Summers C, Annesley C, et al. INSPIRED Symposium Part 2: prevention and management of relapse following chimeric antigen receptor T Cell Therapy for B cell acute lymphoblastic leukemia. Transpl Cell Ther. 2023;29:674\u201384.","journal-title":"Transpl Cell Ther"},{"key":"1388_CR6","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park JH, Rivi\u00e8re I, Gonen M, Wang X, S\u00e9n\u00e9chal B, Curran KJ, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378:449\u201359.","journal-title":"N Engl J Med"},{"key":"1388_CR7","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1200\/JCO.22.01076","volume":"41","author":"LM Schultz","year":"2023","unstructured":"Schultz LM, Eaton A. Outcomes after nonresponse and relapse Post-Tisagenlecleucel in children, adolescents, and young adults with B-cell acute lymphoblastic leukemia. J Clin Oncol. 2023;41:354\u201363.","journal-title":"J Clin Oncol"},{"key":"1388_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01038-2","volume":"14","author":"M Oporto Espuelas","year":"2024","unstructured":"Oporto Espuelas M, Burridge S, Kirkwood AA, Bonney D, Watts K, Shenton G, et al. Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r\/r ALL through a national access scheme. Blood Cancer J. 2024;14:66.","journal-title":"Blood Cancer J"},{"key":"1388_CR9","first-page":"788.e1","volume":"30","author":"I Aldoss","year":"2024","unstructured":"Aldoss I, Shan H, Yang D, Clark MC, Al Malki M, Aribi A, et al. Consolidation with first and second allogeneic transplants in adults with relapsed\/refractory B-ALL following response to CD19CAR T cell therapy. Transpl Cell Ther. 2024;30:788.e1\u2013e9.","journal-title":"Transpl Cell Ther"},{"key":"1388_CR10","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1016\/j.ymthe.2025.03.019","volume":"33","author":"A Dreyzin","year":"2025","unstructured":"Dreyzin A, Shao L, Cai Y, Han KL, Prochazkova M, Gertz M, et al. Immunophenotype of CAR T cells and apheresis products predicts response in CD22 CAR T cell trial for B cell acute lymphoblastic leukemia. Mol Ther. 2025;33:3360\u201374.","journal-title":"Mol Ther"},{"key":"1388_CR11","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.3389\/fimmu.2019.02664","volume":"10","author":"X Xu","year":"2019","unstructured":"Xu X, Sun Q, Liang X, Chen Z, Zhang X, Zhou X, et al. Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies. Front Immunol. 2019;10:2664.","journal-title":"Front Immunol"},{"key":"1388_CR12","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41591-021-01497-1","volume":"27","author":"S Cordoba","year":"2021","unstructured":"Cordoba S, Onuoha S, Thomas S, Pignataro DS, Hough R, Ghorashian S. CAR T-cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B\u2009cell acute lymphoblastic leukemia: a phase 1 trial. Nat Med. 2021;27:1797\u2013805.","journal-title":"Nat Med"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01388-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01388-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01388-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T15:33:46Z","timestamp":1761320026000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01388-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1388"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01388-5","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"assertion":[{"value":"5 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"180"}}